期刊
JOURNAL OF CLINICAL PHARMACOLOGY
卷 51, 期 2, 页码 128-152出版社
WILEY
DOI: 10.1177/0091270010362904
关键词
Biomarkers; diabetes; oxidative stress
资金
- American Diabetes Association
- American Heart Association (National)
- Bugher Foundation
- Janssen Neuroscience Award
- LEARN Foundation
- MI Life Sciences Challenge Award
- Nelson Foundation
- NIH NIEHS [P30 ES06639]
- NIH NIA
- NIH NINDS
- NIH ARRA
Globally, developed nations spend a significant amount of their resources on health care initiatives that poorly translate into increased population life expectancy. As an example, the United States devotes 16% of its gross domestic product to health care, the highest level in the world, but falls behind other nations that enjoy greater individual life expectancy. These observations point to the need for pioneering avenues of drug discovery to increase life span with controlled costs. In particular, innovative drug development for metabolic disorders such as diabetes mellitus becomes increasingly critical given that the number of diabetic people will increase exponentially over the next 20 years. This article discusses the elucidation and targeting of novel cellular pathways that are intimately tied to oxidative stress in diabetes mellitus for new treatment strategies. Pathways that involve wingless, beta-nicotinamide adenine din ucleotide (NAD(+)) precursors, and cytokines govern complex biological pathways that determine both cell survival and longevity during diabetes mellitus and its complications. Furthermore, the role of these entities as biomarkers for disease can further enhance their utility irrespective of their treatment potential. Greater understanding of the intricacies of these unique cellular mechanisms will shape future drug discovery for diabetes mellitus to provide focused clinical care with limited or absent long-term complications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据